Efficacy of ipilimumab 3mg/kg following progression on low dose ipilimumab in metastatic melanoma.

被引：0
|
作者：
Lai-Kwon, Julia Elizabeth
Jacques, Sarah
Carlino, Matteo S.
Benannoune, Naima
Robert, Caroline
Allayous, Clara
Baroudjian, Barouyr
Lebbe, Celeste
Zimmer, Lisa
Eroglu, Zeynep
Topcu, Turkan Ozturk
Dimitriou, Florentia
Haydon, Andrew Mark
Lo, Serigne N.
Menzies, Alexander M.
Long, Georgina V.
机构：
[1] Melanoma Inst Australia, Wollstonecraft, Australia
[2] Crown Princess Mary Canc Ctr, Sydney, NSW, Australia
[3] Blacktown Hosp, Blacktown, Australia
[4] Gustave Roussy, Canc Campus, Villejuif, France
[5] Gustave Roussy, Villejuif, France
[6] Paris Saclay Univ, Paris, France
[7] Hop St Louis, AP HP, Dermatol Dept, Paris, France
[8] St Louis Hosp, AP HP, Dept Dermatol, Paris, France
[9] Univ Paris, Hop St Louis, AP HP, Paris, France
[10] Univ Hosp Essen, Dept Dermatol, Essen, Germany
[11] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[12] H Lee Moffitt Canc Ctr & Res Inst, Dept Cutaneous Oncol, Tampa, FL USA
[13] Univ Zurich Hosp, Zurich, Switzerland
[14] Alfred Hosp, Melbourne, Vic, Australia
[15] Univ Sydney, Melanoma Inst Australia, Sydney, NSW, Australia
[16] Royal North Shore & Mater Hosp, Sydney, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e21533
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Efficacy of ipilimumab 3 mg/kg following progression on low-dose ipilimumab in metastatic melanoma
    Lai-Kwon, Julia
    Jacques, Sarah
    Carlino, Matteo
    Benannoune, Naima
    Robert, Caroline
    Allayous, Clara
    Baroudjian, Barouyr
    Lebbe, Celeste
    Zimmer, Lisa
    Eroglu, Zeynep
    Topcu, Turkan Ozturk
    Dimitriou, Florentia
    Haydon, Andrew
    Lo, Serigne N.
    Menzies, Alexander M.
    Long, Georgina, V
    EUROPEAN JOURNAL OF CANCER, 2023, 186 : 12 - 21
  • [2] Efficacy and safety of ipilimumab 3 mg/kg in patients with pretreated, metastatic, mucosal melanoma
    Del Vecchio, Michele
    Di Guardo, Lorenza
    Ascierto, Paolo A.
    Grimaldi, Antonio M.
    Sileni, Vanna Chiarion
    Pigozzo, Jacopo
    Ferraresi, Virginia
    Nuzzo, Carmen
    Rinaldi, Gaetana
    Testori, Alessandro
    Ferrucci, Pier F.
    Marchetti, Paolo
    De Galitiis, Federica
    Queirolo, Paola
    Tornari, Elena
    Marconcini, Riccardo
    Calabro, Luana
    Maio, Michele
    EUROPEAN JOURNAL OF CANCER, 2014, 50 (01) : 121 - 127
  • [3] Evaluation of the absolute lymphocyte count as a biomarker for melanoma patients treated with the commercially available dose of ipilimumab (3mg/kg)
    Postow, Michael Andrew
    Yuan, Jianda
    Panageas, Katherine
    Bogatch, Kita
    Callahan, Margaret
    Cheng, Michael
    Schroeder, Sebastian Edoardo Artur
    Kendle, Ryan F.
    Harding, James J.
    Dickson, Mark Andrew
    D'Angelo, Sandra P.
    Carvajal, Richard D.
    Schwartz, Gary K.
    Wolchok, Jedd D.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [4] Phase II study of low-dose cyclophosphamide and ipilimumab in metastatic melanoma.
    Pavlick, Anna C.
    Chandra, Sunandana
    Stein, Claire
    Madden, Kathleen M.
    Kannan, Rajni
    Escano, Crystal
    Muren, Caroline
    Yepes, Ethel
    Sabado, Rachel Lubong
    Bhardwaj, Nina
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [5] Ipilimumab plus temozolomide in metastatic melanoma.
    Patel, S. P.
    Bedikian, A. Y.
    Papadopoulos, N. E.
    Hwu, W.
    Kim, K. B.
    Homsi, J.
    Davies, M. A.
    Woodman, S. E.
    Radvanyi, L. G.
    Woodard, K.
    Mahoney, S.
    Hwu, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [6] Efficacy of radiotherapy in patients on progression after treatment with ipilimumab 3 mg/kg
    Antonio M Grimaldi
    Ester Simeone
    Diana Giannarelli
    Paolo Muto
    Sara Falivene
    Fabio Sandomenico
    Antonella Petrillo
    Marcello Curvietto
    Assunta Esposito
    Miriam Paone
    Marco Palla
    Corrado Caracò
    Gennaro Ciliberto
    Nicola Mozzillo
    Paolo A Ascierto
    Journal of Translational Medicine, 12 (Suppl 1)
  • [7] Clinical experience and correlates of ipilimumab 3 mg/kg with GM-CSF in advanced melanoma.
    Luke, Jason John
    Donahue, Hilary
    Nishino, Mizuki
    Giobbie-Hurder, Anita
    Davis, Meredith
    Bailey, Nancy
    Ott, Patrick Alexander
    Hodi, F. Stephen
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [8] Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial
    Ascierto, Paolo A.
    Del Vecchio, Michele
    Robert, Caroline
    Mackiewicz, Andrzej
    Chiarion-Sileni, Vanna
    Arance, Ana
    Lebbe, Celeste
    Bastholt, Lars
    Hamid, Omid
    Rutkowski, Piotr
    McNeil, Catriona
    Garbe, Claus
    Loquai, Carmen
    Dreno, Brigitte
    Thomas, Luc
    Grob, Jean-Jacques
    Liszkay, Gabriella
    Nyakas, Marta
    Gutzmer, Ralf
    Pikiel, Joanna
    Grange, Florent
    Hoeller, Christoph
    Ferraresi, Virginia
    Smylie, Michael
    Schadendorf, Dirk
    Mortier, Laurent
    Svane, Inge Marie
    Hennicken, Delphine
    Qureshi, Anila
    Maio, Michele
    LANCET ONCOLOGY, 2017, 18 (05): : 611 - 622
  • [9] Predictive biomarkers of ipilimumab toxicity in metastatic melanoma.
    Gowen, Michael
    Tchack, Jeremy
    Zhou, Hua
    Giles, Keith Michael
    Paschke, Scott
    Moran, Una
    Fenyo, David
    Tsirigos, Aristotelis
    Pacold, Michael
    Pavlick, Anna C.
    Krogsgaard, Michelle
    Osman, Iman
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [10] Metastatic malignant melanoma. Successfull treatment with ipilimumab
    Jansen, T.
    Bruch-Gerharz, D.
    Reifenberger, J.
    Schulte, K. W.
    HAUTARZT, 2013, 64 (04): : 228 - +
12345